๐Ÿ‘ค Tomoyuki Fujikura

๐Ÿ” Search ๐Ÿ“‹ Browse ๐Ÿท๏ธ Tags โค๏ธ Favourites โž• Add ๐Ÿงฌ Extraction
2
Articles
articles
Takamasa Iwakura, Chiemi Ema, Shinsuke Isobe +4 more ยท 2022 ยท Scientific reports ยท Nature ยท added 2026-04-24
Membranous nephropathy (MN) is the leading cause of nephrotic syndrome in adults. We previously reported that the prevalence of phospholipase A2 receptor (PLA2R)- and thrombospondin type 1 domain cont Show more
Membranous nephropathy (MN) is the leading cause of nephrotic syndrome in adults. We previously reported that the prevalence of phospholipase A2 receptor (PLA2R)- and thrombospondin type 1 domain containing 7A (THSD7A)-associated MN patients in Japan is 52.7% and 9.1%, respectively. In addition to PLA2R and THSD7A, we assessed the presence of newly discovered target antigens, neural epidermal growth factor-like 1 (NELL-1), semaphorin 3B (SEMA3B), and exostosin 1/exostosin 2 (Ext1/Ext2), in renal specimens from patients with primary and secondary MN by immunohistochemistry. We found enhanced glomerular staining of PLA2R, THSD7A, NELL-1, and Ext1/Ext2 in 53.6%, 8.7%, 1.5%, and 13.0% of the renal samples, respectively, in patients with primary MN. None of the patient specimens showed enhanced staining of SEMA3B. Enhanced glomerular staining of PLA2R, NELL-1, and Ext1/Ext2 was detected in 5.7%, 8.6%, and 22.9% of the patients with secondary MN, respectively. Based on our findings, we recommend the assessment of PLA2R, THSD7A and NELL-1 in addition to clinical information and IgG4 staining to differentiate between primary and secondary MN. This would aid in distinguishing secondary MN patients from primary MN patients who coincidentally have some secondary characteristics. Show less
๐Ÿ“„ PDF DOI: 10.1038/s41598-022-07037-2
EXT1
Takamasa Iwakura, Chiemi Ema, Taichi Sato +5 more ยท 2021 ยท Kidney medicine ยท Elsevier ยท added 2026-04-24
Technological advances have allowed the discovery of 6 subtypes of membranous nephropathy based on target antigens: M-type phospholipase A
๐Ÿ“„ PDF DOI: 10.1016/j.xkme.2021.03.013
EXT1